Proteon Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference March 22nd
March 17 2017 - 6:55AM
Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing
novel, first-in-class therapeutics to address the medical needs of
patients with kidney and vascular diseases, today announced that
Company management will present at the Oppenheimer 27th Annual
Healthcare Conference in New York City on Wednesday, March 22, 2017
at 1:35 p.m. ET.
A live audio webcast of the presentation can be
accessed by visiting the Investor and Media section of the
Company’s website at www.proteontherapeutics.com. A replay of
the webcast will be archived on the Proteon website following the
presentation.
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of
patients with kidney and vascular diseases through the development
of novel, first-in-class therapeutics. Proteon's lead product
candidate, vonapanitase, is an investigational drug intended to
improve hemodialysis vascular access outcomes. Proteon is currently
enrolling patients in PATENCY-2, a Phase 3 clinical trial
evaluating vonapanitase in patients with chronic kidney disease
(CKD) undergoing surgical creation of a radiocephalic arteriovenous
fistula for hemodialysis. Proteon is also evaluating vonapanitase
in a Phase 1 clinical trial in patients with peripheral artery
disease (PAD). For more information, please visit
www.proteontx.com.
Investor ContactGeorge Eldridge, Proteon
Therapeutics, Senior Vice President and Chief Financial
Officer781-890-0102geldridge@proteontherapeutics.com
Media ContactAnn Stanesa, Ten
Bridge
Communications617-230-0347proteon@tenbridgecommunications.com
Proteon Therapeutics (NASDAQ:PRTO)
Historical Stock Chart
From Apr 2024 to May 2024
Proteon Therapeutics (NASDAQ:PRTO)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Proteon Therapeutics Inc (NASDAQ): 0 recent articles
More News Articles